March 2021 New Drug Approvals
Azstarys: is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older. (1)
Fotivda: is a newly approved VEGF tyrosine kinase inhibitor indicated for the treatment of renal cell carcinoma (RCC) in adults. This oral therapy is reserved for patients who have relapsed after 2 or more prior systemic therapies.(2)
Axum Rx offers a drug pipeline management solution across pharmacy and medical benefit. With Axum Rx’s pipeline management solution, you can anticipate and mitigate the impact of the drug pipeline on your bottom line today!
Ponvory: is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. (3)
Zegalogue: is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. (4)